Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Published on Mar 1, 2013in European Urology17.947
· DOI :10.1016/J.EURURO.2012.10.039
Jorg R. Oddens17
Estimated H-index: 17
(Bosch),
Maurizio A. Brausi4
Estimated H-index: 4
+ 9 AuthorsWillem Oosterlinck31
Estimated H-index: 31
Sources
Abstract
Abstract Background The optimal dose and duration of intravesical bacillus Calmette-Guerin (BCG) in the treatment of non–muscle-invasive bladder cancer (NMIBC) are controversial. Objective To determine if a one-third dose (1/3D) is not inferior to the full dose (FD), if 1 yr of maintenance is not inferior to 3 yr of maintenance, and if 1/3D and 1 yr of maintenance are associated with less toxicity. Design, setting, and participants After transurethral resection, intermediate- and high-risk NMIBC patients were randomized to one of four BCG groups: 1/3D-1 yr, 1/3D-3 yr, FD-1 yr, and FD-3 yr. Outcome measurements and statistical analysis The trial was designed as a noninferiority study with the null hypothesis of a 10% decrease in the disease-free rate at 5 yr. Times to events were estimated using cumulative incidence functions and compared using the Cox proportional hazards regression model. Results and limitations In an intention-to-treat analysis of 1355 patients with a median follow-up of 7.1 yr, there were no significant differences in toxicity between 1/3D and FD. The null hypotheses of inferiority of the disease-free interval for both 1/3D and 1 yr could not be rejected. We found that 1/3D-1 yr is suboptimal compared with FD-3 yr (hazard ratio [HR]: 0.75; 95% confidence interval [CI], 0.59–0.94; p =0.01). Intermediate-risk patients treated with FD do not benefit from an additional 2 yr of BCG. In high-risk patients, 3 yr is associated with a reduction in recurrence (HR: 1.61; 95% CI, 1.13–2.30; p =0.009) but only when given at FD. There were no differences in progression or survival. Conclusions There were no differences in toxicity between 1/3D and FD. Intermediate-risk patients should be treated with FD-1 yr. In high-risk patients, FD-3 yr reduces recurrences as compared with FD-1 yr but not progressions or deaths. The benefit of the two additional years of maintenance should be weighed against its added costs and inconvenience. Trial registration This study was registered at ClinicalTrials.gov, number NCT00002990; http://clinicaltrials.gov/ct2/show/record/NCT00002990.
📖 Papers frequently viewed together
20041.92Urology
2 Authors (A Böhle, P.R Bock)
348 Citations
1,928 Citations
436 Citations
References22
Newest
#1Maurizio Brausi (AUSL: Academy for Urban School Leadership)H-Index: 38
#2J. Alfred Witjes (Radboud University Nijmegen Medical Centre)H-Index: 88
Last. Andreas BöhleH-Index: 52
view all 10 authors...
Purpose: Although the European Association of Urology, First International Consultation on Bladder Tumors, National Comprehensive Cancer Network and American Urological Association guidelines all provide an excellent evidence-based framework for the management of nonmuscle invasive bladder cancer, these guidelines vary with respect to important issues such as risk level definitions and management strategies for these risk categories. Therefore, we built on the existing framework provided by curr...
224 CitationsSource
#1Shiro Hinotsu (Kyoto University)H-Index: 21
#2Hideyuki Akaza (UTokyo: University of Tokyo)H-Index: 66
Last. Tomoyasu TsushimaH-Index: 25
view all 17 authors...
Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVE • To confirm the recurrence-preventing efficacy and safety of 18-month bacillus Calmette-Guerin (BCG) maintenance therapy for non-muscle-invasive bladder cancer. PATIENTS AND METHODS • The enrolled patients had been diagnosed with recurrent or multiple non-muscle-invasive bladder cancer (stage Ta or T1) after complete transurethral resection of bladder tumours (TURBT). • The patients were randomized into three treatment groups: a maintena...
67 CitationsSource
#1Marko Babjuk (Charles University in Prague)H-Index: 31
#2Willem Oosterlinck (Ghent University Hospital)H-Index: 17
Last. Morgan Rouprêt (UPMC: Pierre-and-Marie-Curie University)H-Index: 74
view all 7 authors...
Abstract Context and objective To present the 2011 European Association of Urology (EAU) guidelines on non–muscle-invasive bladder cancer (NMIBC). Evidence acquisition Literature published between 2004 and 2010 on the diagnosis and treatment of NMIBC was systematically reviewed. Previous guidelines were updated, and the level of evidence (LE) and grade of recommendation (GR) were assigned. Evidence synthesis Tumours staged as Ta, T1, or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis dep...
526 CitationsSource
#1Richard J. Sylvester (European Organisation for Research and Treatment of Cancer)H-Index: 12
#2Maurizio A. Brausi (AUSL: Academy for Urban School Leadership)H-Index: 4
Last. Theo M. de ReijkeH-Index: 42
view all 11 authors...
Background Intravesical chemotherapy and bacillus Calmette-Guerin (BCG) reduce the recurrence rate in patients with stage Ta T1 urothelial bladder cancer; however, the benefit of BCG relative to chemotherapy for long-term end points is controversial, especially in intermediate-risk patients.
282 CitationsSource
#1Richard SylvesterH-Index: 96
#2Maurizio BrausiH-Index: 38
Last. Theo M. de ReijkeH-Index: 42
view all 4 authors...
20 Citations
#1Per-Uno Malmström (Uppsala University Hospital)H-Index: 62
#2Richard Sylvester (European Organisation for Research and Treatment of Cancer)H-Index: 96
Last. J. Alfred Witjes (Radboud University Nijmegen)H-Index: 88
view all 9 authors...
Background: Patients with non-muscle-invasive bladder cancer with an inter- mediate or high risk need adjuvant intravesical therapy after surgery. Based largely on meta-analyses of previously published results, guidelines recommend using either bacillus Calmette-Guerin (BCG) or mitomycin C (MMC) in these patients. Individual patient data (IPD) meta-analyses, however, are the gold standard. Objective: To compare the efficacy of BCG and MMC based on an IPD meta-analysis of randomised trials. Desig...
436 CitationsSource
#1A. Ojea (University Hospital Complex Of Vigo)H-Index: 9
Last. Rosario MaderoH-Index: 41
view all 14 authors...
Abstract Objective The primary aim was to search for lower doses of Bacillus Calmette-Guerin (BCG) that are effective and have lower toxicity. Methods A low dose of BCG 27mg was compared with BCG 13.5mg, using mitomycin C (MMC) 30mg as the third arm of comparison. A total of 430 patients with intermediate-risk superficial bladder cancer were randomised into three groups. Instillations were repeated once a week for 6 wk followed by another six instillations given once every 2 wk during 12 wk. Res...
141 CitationsSource
#1Marc Colombel (UCBL: Claude Bernard University Lyon 1)H-Index: 16
#2Fabien SaintH-Index: 42
Last. Pascal RischmannH-Index: 30
view all 6 authors...
Purpose: We determined whether prophylaxis with ofloxacin could decrease the toxicity of bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. We also investigated the impact of ofloxacin on bacillus Calmette-Guerin antitumor efficacy.Materials and Methods: In this randomized, double-blind, multicenter study 115 patients with primary or recurrent superficial bladder cancer (Ta/T1, CIS, G1-G3) and no prior bacillus Calmette-Guerin treatment were randomized to induction treatmen...
135 CitationsSource
#1Hartwig E. Schwaibold (LMU: Ludwig Maximilian University of Munich)H-Index: 1
#2Sivaprakasam Sivalingam (LMU: Ludwig Maximilian University of Munich)H-Index: 1
Last. Rudolf Hartung (LMU: Ludwig Maximilian University of Munich)H-Index: 25
view all 4 authors...
OBJECTIVE To evaluate a series of repeat transurethral resections (TURs) of tumour in patients with T1 bladder cancer, usually used to ensure a complete resection and to exclude the possibility muscle-invasive disease. PATIENTS AND METHODS In all, 136 consecutive patients had a second TUR because of a histopathological diagnosis of T1 transitional cell carcinoma (TCC) after their initial TUR. Of the 136 patients, 101 were first presentations and 35 had recurrent tumours. The second TUR was done ...
152 CitationsSource
3 CitationsSource
Cited By291
Newest
#1Marko Babjuk (Charles University in Prague)H-Index: 31
#2Maximilian Burger (University of Regensburg)H-Index: 53
Last. A. Hugh MostafidH-Index: 7
view all 17 authors...
Abstract null null Context null The European Association of Urology (EAU) has released an updated version of the guidelines on non–muscle-invasive bladder cancer (NMIBC). null null null Objective null To present the 2021 EAU guidelines on NMIBC. null null null Evidence acquisition null A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines since the 2020 version was performed. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Pre...
2 CitationsSource
Last. G. Marcq (Pasteur Institute)
view all 3 authors...
Resume null null La BCG-therapie a permis une amelioration des resultats oncologiques des TVNIM de risque intermediaire et/ou de haut risque. Cependant, les effets secondaires (ES) sont frequents et peuvent nuire a l’observance. L’objectif de cet article etait de decrire les differents effets secondaires lies aux installations de BCG-therapie et leur prise en charge. La majorite des ES sont classifies comme mineurs et necessitent une simple prescription de paracetamol et d’AINS sans arret du BCG...
Source
#1Olga M Pijpers (EUR: Erasmus University Rotterdam)
#2Kees Hendricksen (NKI-AVL: Netherlands Cancer Institute)H-Index: 11
Last. Joost L. Boormans (EUR: Erasmus University Rotterdam)H-Index: 22
view all 8 authors...
Abstract null null Background null The recommended treatment for patients with Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) is radical cystectomy (RC). However, many patients refuse, or are unfit for RC. Therefore, alternative bladder-sparing treatment modalities are needed for BCG-unresponsive NMIBC. In this study we sought to assess the long-term efficacy of hyperthermic intravesical chemotherapy (HIVEC) as alternative to radical cystectomy in BCG-unre...
1 CitationsSource
#1Sook-Hee Kwon (Pukyong National University)H-Index: 1
#2Il Do Ha (Pukyong National University)H-Index: 8
Last. T. Emura (Kurume University)H-Index: 3
view all 4 authors...
Copula-based survival regression models, which consist of a copula function and marginal distribution (i.e., marginal survival function), have been widely used for analyzing clustered multivariate survival data. Archimedean copula functions are useful for modeling such dependence. For the likelihood inference, one-stage and two-stage estimation methods have been usually used. The two-stage procedure can give inefficient estimation results because of separate estimation of the marginal and copula...
Source
Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. While the clinical approach to BCa has remained largely unchanged for many years, recent discoveries have paved the way to a new era of diagnosis and management of the disease. BCa-specific mortality started to decrease in the regions with a wide range of activities leading to greater social awareness of the risk factors and the decline in carcinogenic exposure. The urologic c...
Source
#1Hannah Slovacek (LUC: Loyola University Chicago)
#2Jerry Zhuo (BCM: Baylor College of Medicine)
Last. Jennifer M. Taylor (BCM: Baylor College of Medicine)H-Index: 2
view all 3 authors...
PURPOSE OF REVIEW Non-muscle-invasive bladder cancer (NMIBC) is a heterogenous malignancy with high recurrence and progression rates, which necessitate uniform recommendations for diagnosis and management. Herein, we review the literature, with an emphasis on guidelines and contemporary diagnostic techniques and interventions. RECENT FINDINGS Guidelines around the world have adopted a schema which risk-stratify cases at diagnosis, to offer evidence-based treatment and surveillance recommendation...
Source
#1Daichi Kikuchi (Iwate Medical University)
#2Yoichiro Kato (Iwate Medical University)H-Index: 10
Last. Wataru Obara (Iwate Medical University)H-Index: 19
view all 17 authors...
Objectives:The aim of this study was to investigate the relationship between quality of life (QOL) and residual urine volume in patients undergoing bacille Calmette-Guerin (BCG) therapy.Methods:Pat...
Source
#1Matthew D. Galsky (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 63
#2Arjun Vasant Balar (NYU: New York University)H-Index: 20
Last. Joshua J. Meeks (Veterans Health Administration)H-Index: 44
view all 15 authors...
A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identifica...
Source
#1Joshua M. Kuperus (Spectrum Health)H-Index: 1
#2Ross D. Busman (Spectrum Health)
Last. Brian R. Lane (Spectrum Health)H-Index: 21
view all 8 authors...
ABSTRACT null null Objectives null To compare patient-reported side effects and tolerability of full-dose Bacillus Calmette-Guerin (BCG), reduced-dose BCG, and gemcitabine one week after administration. null null null Methods null All patients from July 2019 to November 2020 receiving intravesical therapy (IVT) for non-muscle invasive bladder cancer (NMIBC) at our institution were surveyed before repeat instillation. Survey questions recorded IVT retention times and the duration and severity of ...
Source
#1Kenneth R MacKenzie (James Cook University Hospital)
#2Sidney D Parker (James Cook University Hospital)
Last. Joanne Cresswell (James Cook University Hospital)H-Index: 12
view all 4 authors...
Objective:Intravesical bacillus Calmette–Guerin (BCG) is the first-line treatment of choice for high-risk non-muscle-invasive bladder cancer (NMIBC). Our aim was to evaluate the long-term impact of...
Source